(via TheNewswire)
“2023 was an extremely busy year for Cytophage in terms of commercializing our key animal health products while also initiating all the necessary steps to take the Company public. Our growing operations have set us up for success in 2024.” said Dr.
The Company’s start to 2024 has already seen major accomplishments:
Cytophage is the first phage company to go public in
Canada .Cytophage is the first phage company to provide phage therapy in
Canada for a prosthetic joint infection.Construction started on itsnew 20,000 sq ft facility that will include a state-of-the-art laboratory, GMP-certified manufacturing suite, administrative offices and warehouse space. It is expected to open in
June 2024 .
The Company’s main focus is on commercializing market-ready phage products for animal health, particularly to addressSalmonellaandE. coliin the poultry market. Cytophage continues to work with Renata Ltd. in
Cytophage will expand its commercialization efforts in
While commercializing animal phage products is the Company’s priority, Cytophage also developed its first human phage therapy for a compassionate use case. “We are proud of therecent landmark trial at The
Greater attention is being paid to the phage sector, with an increased number of compassionate use cases being highlighted in the media. In Canada, CBC and CTV did national news segments on Cytophage’s prosthetic joint infection phage therapy case. In the
2023 Milestones
Animal Health Division
Cytophage entered into a Distribution Agreement with Renata Limited-Animal Health Division in
Dhaka, Bangladesh (“Renata”) for the distribution of Cytophage’s animal health products by Renata inBangladesh ,Myanmar ,Nepal andSri Lanka .Cytophage submitted its first ever GRAS notice to the
Office of Food Additive Safety of the FDA , which such notice concluded, through scientific procedures, that the phage cocktail targeted for use on chicken meat is generally regarded as safe and is not subject to pre-market approval requirements for use in food.The Company then proceeded to submit its first ever LONO to the
Health Products and Food Branch ofHealth Canada to review the use of its phage product targeted for use on chicken meat as an antimicrobial food processing aid to reduce Salmonella on the surface of raw, skinless and boneless poultry meat.Cytophage completed a number of studies related to its poultry phage product for addressingSalmonellaandE. coliinfections in chickens. The studies showed that the product not only reduced the lethality and decreased the transmission of the bacteria in broiler chicken and layer hens, it resulted in healthier and heavier birds that were ready for market sooner than untreated birds. These studies include:
ooEvaluating the poultry phage product’s ability to reduceSalmonellatransmission. The study showed that, in broiler chickens, the phage product removes the lethal effect ofSalmonellaandE. coliand decreases transmission of bacterial infections within the flock. The result was healthier chickens and increased weight gain.
ooEvaluating the ability of the phage product to protect layer hens fromSalmonellaandE. coli. The study results showed that the phage product removed the lethal effect ofSalmonellaandE. coli. As well, it decreased colonization in birds if an infection was present and decreased transmission of bacterial infection within the flock.
ooEvaluating the ability of the phage product to protect broiler chickens fromSalmonellaandE. coliin
Bangladesh . The study found that the treated birds were healthier and heavier than untreated birds. Further, mortality was decreased by more than 20%.
Evaluating theClostridium perfringensphage product in poultry. Cytophage developed an animal model for lethality which then allowed for testing of its phage product against necrotic enteritis disease in broilers. The study showed that necrotic enteritis disease severity is reduced in broiler chickens infected withClostridium perfringenswhen using the phage product.
Evaluating the ability of the phage product to reduceSalmonellaon experimentally contaminated chicken meat. The study results showed that the phage product significantly reduced the viableSalmonellapopulation when applied to contaminated skinless, boneless chicken meat.
Human Health Division
In late 2023, Cytophage was contacted by physician, infectious diseases clinician-scientist Dr.
Corporate Developments
During Q2 of 2023, the Company began laying the groundwork for a planned initial public offering in early 2024.In May, Cytophage entered into a Letter of Intent with
Cuspis Capital III Ltd. to complete a business combination and concurrent financing.In May, Cytophage secured a 20,000 sq. ft. facility that will be renovated to be its worldwide headquarters and is expected to open in
June 2024 .In November, Cytophage,
Cuspis Capital III Ltd. and 10179321Manitoba Ltd. , a wholly-owned subsidiary of theCuspis Capital III Ltd. , entered into a business combination agreement.In December, the Company finalized the financing for gross proceeds of
$2,500,000 which was in addition to the$522,000 financing closed in the summer of 2023.
For further information please contact:
Chief Operating Officer
heather@cytophage.com
431 388 8873
Cytophage Investor Alerts:https://cytophage.com/subscribe/
About Cytophage Technologies
Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressingthe global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.
Cautionary Statement on Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are
described under the caption “Risk Factors” in Cytophage’s Filing Statement dated
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source